 Tamoxifen
"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
Soltamox- Soltamox
- Savient brand of Tamoxifen Citrate
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 2 | 0 | 2 | | 1982 | 0 | 1 | 1 | | 1983 | 1 | 2 | 3 | | 1984 | 1 | 0 | 1 | | 1985 | 0 | 3 | 3 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 1 | 1 | | 1988 | 0 | 2 | 2 | | 1989 | 1 | 1 | 2 | | 1990 | 0 | 1 | 1 | | 1992 | 1 | 1 | 2 | | 1993 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 2 | 4 | | 1997 | 3 | 0 | 3 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 3 | 4 | | 2000 | 1 | 2 | 3 | | 2001 | 3 | 2 | 5 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 2 | 4 | | 2004 | 3 | 3 | 6 | | 2005 | 0 | 2 | 2 | | 2006 | 3 | 1 | 4 | | 2007 | 0 | 1 | 1 | | 2008 | 3 | 3 | 6 | | 2009 | 1 | 1 | 2 | | 2010 | 3 | 2 | 5 | | 2011 | 7 | 2 | 9 | | 2012 | 3 | 2 | 5 | | 2013 | 6 | 3 | 9 | | 2014 | 5 | 5 | 10 | | 2015 | 3 | 4 | 7 | | 2016 | 6 | 3 | 9 | | 2017 | 1 | 3 | 4 | | 2018 | 3 | 1 | 4 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Hruska CB, Hunt KN, Conners AL, Geske JR, Brandt KR, Degnim AC, Vachon CM, O'Connor MK, Rhodes DJ. Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. Breast Cancer Res. 2019 03 08; 21(1):38.
-
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
-
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
-
Maximov PY, Abderrahman B, Fanning SW, Sengupta S, Fan P, Curpan RF, Rincon DMQ, Greenland JA, Rajan SS, Greene GL, Jordan VC. Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol. 2018 08; 94(2):812-822.
-
Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
-
Rein LA, Wisler JW, Kim J, Theriot B, Huang L, Price T, Yang H, Chen M, Chen W, Sipkins D, Fedoriw Y, Walker JK, Premont RT, Lefkowitz RJ. ß-Arrestin2 mediates progression of murine primary myelofibrosis. JCI Insight. 2017 12 21; 2(24).
-
Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gómez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perelló A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.
-
Salibian AA, Bokarius AV, Gu J, Lee Y, Wirth GA, Paydar KZ, Kobayashi MR, Evans GR. Reply: Perioperative Tamoxifen Use and Risk of Deep Vein Thrombosis: Role of Caprini Risk Assessment Model Should not be Discarded: Is It Necessary to Stop Tamoxifen Therapy in Microvascular Flap Reconstruction? Ann Plast Surg. 2017 04; 78(4):477.
-
Aymard F, Aguirrebengoa M, Guillou E, Javierre BM, Bugler B, Arnould C, Rocher V, Iacovoni JS, Biernacka A, Skrzypczak M, Ginalski K, Rowicka M, Fraser P, Legube G. Genome-wide mapping of long-range contacts unveils clustering of DNA double-strand breaks at damaged active genes. Nat Struct Mol Biol. 2017 04; 24(4):353-361.
-
Salibian AA, Bokarius AV, Gu J, Lee Y, Wirth GA, Paydar KZ, Kobayashi MR, Evans GR. The Effects of Perioperative Tamoxifen Therapy on Microvascular Flap Complications in Transverse Rectus Abdominis Myocutaneous/Deep Inferior Epigastric Perforator Flap Breast Reconstruction. Ann Plast Surg. 2016 Dec; 77(6):630-634.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|